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Relationship Between Serum Level of Fibroblast Growth Factor-23
(FGF-23) and Calcium and Phosphate Metobolism of Patients with
Chronic Kidney Disease
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The First Affiliated Hospital of Baotou Medical College, Baotou, China
Objective: To investigate the relationship between serume level of fibro-
blast growth factor-23 (FGF-23) and calcium and phosphate of patients
with chronic kidney disease.
Methods: Intact FGF-23 and 1,25(OH)2 vitamin D3 were detected by enzyme-
linked immunosorbent assay (ELISA) in CKD 151 patients with various degree
of renal function and fourteen healthy controls, at the same time, some
other parameters including creatinine, serum phosphate, calcium, parathyr-
iod hormone, uric acid and alkaline phosphatese were measured. Further,
the relationship between FGF-23 and other biochemical variables was
analysed.
Results: (1) The level of serum FGF-23 was gradually elevated at CKD stage
1,2e3,4e5, there were significant difference in CKD stage 2e3 and 4e5
compared respectively with normal controls (P < 0.01), and in CKD stage
4e5 compared with CKD stage 1 and 2e3 (P < 0.01). (2) In the CKD stage
1e5 the level of serum FGF-23 by Pearson relativity analysis was significantly
correlated positively with creatinine (r Z 0.97, P < 0.01), phosphate
(r Z 0.65, P < 0.01), and parathyroid hormone (r Z 0.536, P < 0.01). The
level of serum FGF-23 by Pearson relativity analysis was significantly corre-
lated negatively with eGFR (r Z 0.578, P < 0.01), 1,25(OH)2 vitamin D3
(r Z 0.586, P < 0.01). (3) In the CKD stage 1e5, creatinine, 1,25(OH)2
vitamin D3 and parathyroid hormone were significant variables that influ-
enced the level of serum FGF-23 in multiple regression analysis.
Conclusion: FGF-23 concentrations were gradually elevated in three groups
of patients with CKD, serum phosphorus, 1,25(OH)2D3, intact PTH and creat-
inine are the major regulators that influenced FGF-23.0051
Table 2 151例CKD患者FGF-23与相关变量的相关分析
NZ 151 r-value P-value
CREA 0.971 <0.01
eGFR -0.578 <0.01
1.25(OH)2D3 -0.586 <0.01
Ca -0.327 <0.01
P 0.650 <0.01
Ca*P 0.477 <0.01
UA 0.173 0.033
ALP 0.143 0.079
PTH 0.536 <0.01http://dx.doi.org/10.1016/j.hkjn.2015.09.1480051
Table 1 CKD1-5期患者血清各指标的比较(x  s)
CREA eGFR FGF-23 1.25
(mmol/l) (ml/min/1.73 m2) (pg/ml) (pg/
正常对照组 43.8  2.71 118.81  5.42 20.82  1.20 595
NZ 14 (x  s)
CKD1期 69.82  13.20 112.62  8.18 71.19  8.26 546
NZ 22 (x  s)
CKD2-3期 139.90  35.19 58.97  16.96) 81.73  13.23) 531
NZ 47 (x  s)
CKD4-5期 440.74
 331.36)6
15.75
 7.67)6
198.05
 111.68)6
409
 1NZ 82 (x  s)
方差分析 F 28.67 593.98 38.46 19.9
P <0.01 <0.01 <0.01 <0.
*和对照组比较，P<0.05；6与CKD1、CKD2-3比较，P<0.05.0052
Function of Reduced Blood Pressure by Compound a-Ketoacid in Non-
dialysis Patients with CKD Stage 3e5
Li SongYang
Jinan Central Hospital, Shanghai, China
Objective: Evaluate the effect of blood pressure-lowering by a-ketoacid in
patients with CKD.
Methods: Selected non-dialysis patients who had hypertension of CKD 3e5
grade, except three cases. All of the patients had taken anti-hypertension
medicine over 3 months. They were treated for an average of 34.5  38.7
months, but SBP was still  140 mmHg and DBP  90 mmHg. A total of 102
patients were included in the statistical analysis. Among them, 61 were
male and 41 were female. Mean age was 70.78  12.34 years (range, 27 to
86 years). 51 cases were CKD stage 3, 31 cases were CKD stage 4, 20 cases
were CKD stage 5. Mean duration of chronic renal insufficiency was
32.7  33.3 months (range, 4 to 120 months). Mean duration of hypertension
was 232.4  174.4 months (range, 4 to 636 months). A low protein diet
(0.6 g/kg.d) and compound a-ketoacid (2.52 g, tid) were given to all pa-
tients. At the same time, the anti-hypertension drugs were not changed dur-
ing the study. After 6 months, statistical analysis was used to compare blood
pressure, PTH and renal function changes before and after treatment.
Results: In 102 cases, total efficiency rate was 83.3%. Mean systolic blood pres-
sure was 163.4  15.8 mmHg before treatment and 137.8  14.8 mmHg after
treatment. Mean diastolic blood pressure was 87.9 12.9 mmHg before treat-
ment and 77.0  9.6 mmHg after treatment (P < 0.01). Mean systolic blood
pressure decreased 25.9  14.8 mmHg and diastolic blood pressure decreased
10.8  9.7 mmHg. There were statistically significant differences. PTH had
markedly decreased after treatment, but there was no statistically significant
differences in renal function before and after treatment.
Conclusion: Low protein diet combining compound a-ketoacid may help to
control hypertension in CKD patients.http://dx.doi.org/10.1016/j.hkjn.2015.09.149
0055
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Objective: Chronic obstructive pulmonary disease (COPD) increases all-
cause mortality and cardiovascular (CV) events in general population. How-
ever, rare study investigates the death and CV risks among chronic kidney(OH)2D3 Ca P Ca*P PTH
ml) (mmol/L) (mmol/L) (mmol2/L2) (pg/l)
.11  10.03 2.27  0.19 1.15  0.13 2.61  0.43 33.81  1.47
.78  102.66 2.27  0.17 1.23  0.15 2.79  0.41 38.59  3.29
.12  114.74 2.24  0.22 1.35  0.15) 3.02  0.40 68.14  30.13
.03
30.51)6
2.10  0.21 1.81
 0.13)6
3.80  0.43 225.41
 172.42)6
7.22 209.01 26.44 69.22
01 <0.01 <0.01 <0.01 <0.01
S108 Chronic Kidney Diseasedisease (CKD) with COPD. This population-based cohort study aimed to eval-
uate the all-cause mortality and major CV events of COPD among CKD pa-
tients using national health insurance (NHI) database in Taiwan.
Methods: CKD patients enrolled in the pre-end stage renal disease (pre-
ESRD) care management program, patients  40 years old who had at least
one outpatient diagnosis code (ICD-9 codes 585, 581.9) or at least one inpa-
tient diagnosis code and free of any dialysis or renal transplant from 1
January 2007 to 31 December 2011 were included. CKD patients with
COPD were matched to control subjects without COPD at a 1:1 ratio using
propensity scores. Cox proportional hazards regression models were used
to estimate hazard ratios (HRs) for all-cause mortality and major CV events
analysis.
Results: Propensity score matching yielded a cohort balanced on age, sex,
urbanization, socioeconomic status, enrolled year, comorbidities, Charl-
son Comorbidity Index score, clinical laboratory data, and medications
used, with 2498 CKD patients in the COPD group and 2498 in the non-
COPD group. CKD patients with COPD were associated with a higher risk
for death (HR, 1.134; 95% CI, 1.037e1.241) and non-significant risk for ma-
jor CV events (HR, 1.041; 95% CI, 0.905e1.198) compared to those without
COPD.
Conclusion: CKD patients with COPD are associated with higher all-cause
mortality and might increase risk of major CV events.http://dx.doi.org/10.1016/j.hkjn.2015.09.150
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Association Between Anemia and Abnormal Bleeding Times in Patients
with Chronic Kidney Disease
Ha Yeon Kim
Chonnam National University Medical School, Gwangju, Republic of Korea
Objective: Platelet dysfunction associated hemorrhagic complications and
chronic anemia are often encountered in patients with chronic kidney dis-
ease. The present study aimed to evaluate the association of anemia and
abnormal bleeding time in patients with chronic kidney disease.
Methods: We retrospectively analyzed the data of 1022 (60.24  15.89
years, men 58.7%). patients with chronic kidney disease.
Results: Patients with prolonged bleeding time (bleeding time > 182 sec)
were older age and lower eGFR, Hgb, Hct and PLT, and higher BUN and Cr
levels compared to those with normal bleeding time. The prevalence of
abnormal bleeding time was found to be higher as Hgb declined [25.0% for
patients with Hgb  10 mg/dl (n Z 595), 31.9% for patients with 8 
Hgb < 10 mg/dl (n Z 343), and 43.4% for patients with Hgb < 8 mg/dl
(n Z 84), P < 0.001, respectively]. eGFR was decreased as Hgb declined
(29.8  19.0 mL/min/1.73 m2 in patients with Hgb  10 mg/dl,
16.0  13.0 mL/min/1.73 m2 in patients with 8  Hgb < 10 mg/dl, and
10.3  8.61 mL/min/1.73 m2 in patients with Hgb < 8 mg/dl, P < 0.001,
respectively). Multivariate analysis revealed that age (OR, 1.019; 95% CI,
1.010e1.029), 8 mg/dl  Hgb < 10 mg/dl (OR, 1.214; 95% CI,
0.873e1.686), Hg < 8 mg/dl (OR, 1.820; 95% CI, 1.084e3.055), 15 mL/
min/1.73 m2  eGFR < 30 mL/min/1.73 m2 (OR, 1.616; 95% CI,
1.053e2.481), eGFR < 15 mL/min/1.73 m2 (OR, 1.668; 95% CI,
1.160e2.397), thrombocytopenia (PLT < 150  109/L) (OR, 2.659; 95% CI,
1.981e3.569) were independently associated with prolonged bleeding time.
Conclusion: Severe anemia (Hgb < 8 mg/dl) is independently associated
with prolonged bleeding time in chronic kidney disease, even after adjusting
for eGFR and other potential confounders.Fig.1 A. Multiple juxtra-articular masses near bilateral elbow joints,
wrist joints, metacarpophalangeal joints, interphalangeal joints, toe joints
and knee joints. B, C, D , E , F. X-ray manifestations: mass-like calcification
shadows in the peripheries of multiple joints all over the body; subcapital
fracture of right femur; linear calcification of middle and small arteries of
limbs, calcification of reticular vessels.http://dx.doi.org/10.1016/j.hkjn.2015.09.151
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Low Plasma Level of Cathelicidin is Associated with Decreased eGFR
Ha Yeon Kim, Seung Jin Lee
Chonnam National University Medical School, Gwangju, Republic of Korea
Objective: This study assessed plasma cathelicidin, 25-OH vitamin D, and
natural killer (NK) cells which play an important role in innate immunity.
Methods: The study cohort included 175 patients who have a variety of esti-
mated glomerular filtration rate (eGFR) at the Chonnam National University
Hospital. Plasma catehlicidin level was measured by ELISA and absolutecount of NK cell was determined by flow cytometry. NK cell was identified
phenotypically as CD3-CD56+.
Results: The study population was divided into 3 groups according to the
eGFR: Group I, eGFR  60 mL/min/1.73 m2, n Z 33 (18.9%); group II, 15
 eGFR < 60 mL/min/1.73 m2, n Z 47 (26.8%); group III, eGFR < 15 mL/
min/1.73 m2, n Z 95 (54.3%), respectively. Plasma cathelicidin level was
decreased with lower eGFR (189.3  18.21 ng/ml in group I,
182.6  17.69 ng/ml in group II, and 179.7  17.76 ng/ml in group III,
P Z 0.032, respectively). On the other hand, percentages and absolute
numbers of NK cells were significantly higher in the peripheral blood of pa-
tients with lower eGFR (1897.7  1584.05 in group I, 2110.8  2168.37 in
group II, and 2833.8  2149.65 in group III, P Z 0.034, respectively). A
25-OH vitamin D was not distinguished in these groups, but after an exclu-
sion of pateints with hemodialysis, 25-OH vitamin D level showed
decreasing tendency with lower eGFR (16.4  6.22 ng/ml in group I,
12.4  4.74 ng/ml in group II, and 11.2  4.96 ng/ml in group III,
P Z 0.166, respectively).
Conclusion: Plasma cathelicidin level was significantly decreased with lower
eGFR while an absolute count of NK cells was increased with lower eGFR,
which might be associated with dysfunction of NK cells. After an exclusion
of patients with hemodialysis, 25-OH vitamin D concentration showed
decreasing tendency with lower eGFR.http://dx.doi.org/10.1016/j.hkjn.2015.09.152
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Calciphylaxis and Hydroxyapatite Crystal Deposition in a Patient with
Uremia
Wu Yongyao
Beilun Branch of the First Affiliated Hospital, Zhejiang University School of
Medicine, Ningbo, China
A 42-year-old male patient with uremia on hemodialysis was admitted due
to right foot ulcer and infection. Two years ago, he lost sight in the right
eye due to calcium salt deposition. One year ago, he developed multiple
peri-articular masses with progressive enlargement, which were identified
as hydroxyapatite. Acral gangrene occurred repeatedly throughout the
course of disease. Radiology indicated diffuse and continuous calcification
of middle and small arteries. Concomitant calcific uremic arteriolopathy
and hydroxyapatite crystal deposition disease were considered. The
diseases originated from abnormal disposition of hydroxyapatite in
conjunctiva, vessels and articular peripheries and shared a common
pathogenesis.
